Product · #12 of 27 · multi-symptom

O Positiv MENO Menopause Gummies

Gummy (capsule & sugar-free options) from O Positiv, made by O Positiv. Daily serving: 2 gummies (or 2 capsules).

Last updated · Price and ratings checked Nov 19, 2026

In short: O Positiv MENO Menopause Gummies scores 50.8/100 in our ranking (#12 of 27). It costs $1.40 a day at the regular price. Evidence: KSM-66 ashwagandha 300 mg + black cohosh 40 mg; best ingredient grade C (Ashwagandha). No NSF registry listing was confirmed.

Pros

  • Widely reviewed: ★ 4.2 from 2,387 Amazon ratings.

Cons

  • No NSF registry listing confirmed.
  • Contains black cohosh: rare liver-injury reports, and adulteration is common across the category.

Flags

Liver caution

Score breakdown

Evidence
21/40
NSF-verified testing
4/20
Value ($/day)
10.7/20
Ingredients
10/10
Amazon rating
5.1/10

How we score

Full label: what's in it

Supplement Facts actives per daily serving (2 gummies (or 2 capsules)). Source: label or official page, checked Nov 19, 2026.
Ingredient (as labeled)Per dayEvidence page
Ashwagandha KSM-66 root extract300 mgAshwagandha C
Chasteberry (Vitex) fruit extract40 mgVitex (chasteberry) C-
Black cohosh root extract40 mgBlack cohosh C
Vitamin D315 mcgVitamin D & calcium B
Vitamin B62 mgNot in our evidence library
Chromium (picolinate)amount not capturedamount not disclosedNot in our evidence library

Doses come from the capsule version's label on the official page; we assumed the gummy has the same actives. Unverified

Evidence

Our evidence score: 21/40, because: KSM-66 ashwagandha 300 mg + black cohosh 40 mg.

Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.

Ingredient evidence

  • Ashwagandha C (300 mg here)
    Ashwagandha root extract has been studied for occasional stress, sleep quality and common symptoms in perimenopause and menopause* in a few small placebo-controlled trials, all run in India. The Menopause Society 2023: Not assessed.
  • Vitex (chasteberry) C- (40 mg here)
    Vitex (chasteberry) has better evidence for menstrual-cycle comfort than for menopause. The largest menopause trial (100 women, combined with St John's wort) found no benefit over placebo. The Menopause Society 2023: Not recommended (Level II).
  • Black cohosh C (40 mg here)
    Black cohosh is the most-studied herb for occasional hot flashes and night sweats associated with menopause*. Independent trials and a Cochrane review found no clear benefit over placebo, other reviews found a small one, and rare liver-injury reports exist. The Menopause Society 2023: Not recommended (Level I) – 'insufficient evidence to support use for VMS'.
  • Vitamin D & calcium B (15 mcg here)
    Calcium and vitamin D support bone health*. Large trials, including the Women's Health Initiative, show a small effect on bone density, and effects on fractures are mixed. The Menopause Society 2023: Not part of VMS statement.

Studies

Studies on its ingredients (19)
  • Effect of an ashwagandha (Withania Somnifera) root extract on climacteric symptoms in women during perimenopause: A randomized, double-blind, placebo-controlled study.

    Gopal S, Ajgaonkar A, Kanchi P et al. · J Obstet Gynaecol Res 2021 · Ashwagandha

    100 Indian women in perimenopause took ashwagandha root extract (300 mg twice a day) or placebo for 8 weeks. Menopause symptoms and quality of life improved more with ashwagandha, and hormone levels shifted. The study was short and not yet repeated outside India.

    Who
    100 perimenopausal women (91 completed)
    Dose
    ashwagandha root extract 300 mg twice daily
    Duration
    8 weeks
    Result
    Total MRS and MENQoL improved vs placebo; estradiol up, FSH/LH down.
    Funding
    Not stated in abstract; Indian investigators (ingredient-supplier funding typical but not verified). Funding not stated

    PubMed · Full text (DOI)

  • A prospective, randomized, double-blind, placebo-controlled study on efficacy and safety of Ashwagandha root extract (Withania somnifera) for managing menopausal symptoms in women.

    Vani I, Muralidhar G, Rao BS · Front Reprod Health 2025 · Ashwagandha

    60 Indian women took ashwagandha root extract or placebo for 8 weeks; symptoms, hot flashes and stress improved more with ashwagandha. Small and short.

    Who
    60 women aged 45–55
    Dose
    ashwagandha root extract
    Duration
    56 days
    Result
    MRS, hot-flash events and stress scores improved vs placebo.
    Funding
    Authors declared no conflicts. Independent / academic

    PubMed · Full text (DOI)

  • Effects of Withania somnifera root extract on sleep quality, body composition, and menopausal symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled trial.

    Obhrai S, Shenoy S, Arora M · Menopause 2026 · Ashwagandha

    66 Indian postmenopausal women took ashwagandha 600 mg a day or placebo for 12 weeks; sleep and menopause symptoms improved more with ashwagandha.

    Who
    66 postmenopausal women (63 completed)
    Dose
    ashwagandha root extract 600 mg/day
    Duration
    12 weeks
    Result
    Better sleep quality (PSQI -5.2 vs -0.8), menopause symptoms and body fat vs placebo; no BMD change.
    Funding
    No conflicts reported. Independent / academic

    PubMed · Full text (DOI)

  • Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial.

    van Die MD, Burger HG, Bone KM et al. · Menopause 2009 · St John's wort + black cohosh, Vitex (chasteberry)

    100 Australian women took a St John's wort + chasteberry combination or placebo for 16 weeks. It did not beat placebo – the largest, most rigorous vitex trial.

    Who
    100 women
    Dose
    St John's wort + Vitex combination
    Duration
    16 weeks
    Result
    No difference vs placebo for hot flushes, Greene scale or depression.
    Funding
    Academic (Australia). Independent / academic

    PubMed · Full text (DOI)

  • Comparison of Vitex agnus-castus Extracts with Placebo in Reducing Menopausal Symptoms: A Randomized Double-Blind Study.

    Naseri R, Farnia V, Yazdchi K et al. · Korean J Fam Med 2019 · Vitex (chasteberry)

    52 Iranian women took chasteberry or placebo for 8 weeks; symptom questionnaires improved more with vitex. Small and questionnaire-based.

    Who
    52 women (Iran)
    Dose
    Vitex agnus-castus extract
    Duration
    8 weeks
    Result
    Total menopausal, anxiety and vasomotor scores lower vs placebo.
    Funding
    No conflicts reported. Independent / academic

    PubMed · Full text (DOI)

  • Black cohosh (Cimicifuga spp.) for menopausal symptoms.

    Leach MJ, Moore V · Cochrane Database Syst Rev 2012 · Black cohosh

    An independent Cochrane review pooled 16 trials with about 2,000 women taking black cohosh (usually 40 mg a day for around 5 months). Women taking black cohosh did not have fewer hot flashes than women on a dummy pill, and the reviewers called the safety data inconclusive.

    Who
    16 RCTs, 2,027 women
    Dose
    median 40 mg/day black cohosh extract
    Duration
    mean 23 weeks
    Result
    No difference vs placebo in hot-flush frequency (MD +0.07/day; 95% CI -0.43 to 0.56; 3 trials, 393 women) or symptom scores; hormone therapy beat black cohosh.
    Funding
    Cochrane review (independent). Independent / academic

    PubMed · Full text (DOI)

  • Black cohosh extracts in women with menopausal symptoms: an updated pairwise meta-analysis.

    Sadahiro R, Matsuoka LN, Zeng BS et al. · Menopause 2023 · Black cohosh

    A 2023 analysis of 22 studies (about 2,300 women) found black cohosh extracts did somewhat better than placebo for overall menopause symptoms and hot flashes, with a small-to-moderate effect. It did not help anxiety or low mood, and the studies varied a lot in product and quality.

    Who
    22 articles, 2,310 women
    Dose
    various black cohosh extracts
    Duration
    various
    Result
    Pooled improvement vs placebo in overall menopausal symptoms (Hedges g 0.58) and hot flashes (g 0.32); no significant effect on anxiety or depression.
    Funding
    Academic; one author reported speaker fees from supplement/pharma companies incl. Cimic. Some author ties

    PubMed · Full text (DOI)

  • Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence.

    Castelo-Branco C, Gambacciani M, Cano A et al. · Climacteric 2021 · Black cohosh, St John's wort + black cohosh

    This review looked only at the specific black cohosh extract in Remifemin and found it beat placebo for menopause symptoms, especially at higher doses or combined with St John's wort. Several authors work for the company that makes Remifemin, so read it as a manufacturer-backed summary.

    Who
    35 studies + 1 MA, 43,759 women (13,096 on iCR)
    Dose
    isopropanolic extract (iCR, Remifemin), 20–>40 mg/day
    Duration
    various
    Result
    SMD -0.69 vs placebo for neurovegetative/psychological symptoms; larger effect at higher dose and with St John's wort; no hepatotoxicity signal in trial data.
    Funding
    Co-authored by staff of Schaper & Brümmer (maker of Remifemin) – manufacturer-affiliated. Industry-linked

    PubMed · Full text (DOI)

  • Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.

    Osmers R, Friede M, Liske E et al. · Obstet Gynecol 2005 · Black cohosh

    About 300 women with menopause symptoms took Remifemin-type black cohosh (40 mg a day) or a dummy pill for 12 weeks. Symptom scores improved more with black cohosh, mostly in women early in menopause, and side effects were similar to placebo.

    Who
    304 women
    Dose
    iCR (Remifemin) equivalent to 40 mg root/day
    Duration
    12 weeks
    Result
    More effective than placebo on the Menopause Rating Scale (P<.001), mainly in early menopause; hot-flush subscore was the most responsive.
    Funding
    Funding not stated in the abstract (study of the manufacturer's extract). Funding not stated

    PubMed · Full text (DOI)

  • Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.

    Pockaj BA, Gallagher JG, Loprinzi CL et al. · J Clin Oncol 2006 · Black cohosh

    In a publicly funded US trial, 132 women took black cohosh (20 mg twice a day) or placebo for 4 weeks each. Hot flashes dropped slightly more on placebo than on black cohosh, so the trial found no benefit.

    Who
    132 women (history of or concern about breast cancer; crossover)
    Dose
    black cohosh 20 mg twice daily
    Duration
    two 4-week periods (crossover)
    Result
    Hot-flash frequency fell 17% on black cohosh vs 26% on placebo (P=.36) – no benefit.
    Funding
    NCCTG/NCI cooperative group (public funding). Independent / academic

    PubMed · Full text (DOI)

  • Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.

    Newton KM, Reed SD, LaCroix AZ et al. · Ann Intern Med 2006 · Black cohosh, Soy isoflavones & genistein

    The US government-funded HALT study followed 351 women for a year. Black cohosh (160 mg a day), a 10-herb blend, and the blend plus more soy food did no better than a dummy pill for hot flashes, while hormone therapy clearly worked.

    Who
    351 women aged 45–55
    Dose
    black cohosh 160 mg/day; multibotanical; multibotanical + soy diet; hormone therapy; placebo
    Duration
    12 months
    Result
    No herbal arm differed from placebo at 3, 6 or 12 months (<1 hot flash/day difference); hormone therapy reduced ~4 symptoms/day vs placebo.
    Funding
    US NIH (NCCAM/NIA) – HALT study, independent. Independent / academic

    PubMed · Full text (DOI)

  • Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.

    Geller SE, Shulman LP, van Breemen RB et al. · Menopause 2009 · Black cohosh, Red clover

    In a year-long, government-funded trial, women took black cohosh, red clover, hormone therapy or a dummy pill. Only hormones beat placebo for hot flashes; both herbs looked safe but did not reduce hot flashes more than placebo.

    Who
    89 women (4 arms)
    Dose
    standardized black cohosh and red clover extracts vs CEE/MPA vs placebo
    Duration
    12 months
    Result
    Hot-flash reduction: black cohosh 34%, red clover 57%, placebo 63%, hormones 94%; neither botanical beat placebo. Both appeared safe over 12 months.
    Funding
    NIH (NCCAM/ODS) botanical center, University of Illinois – independent. Independent / academic

    PubMed · Full text (DOI)

  • Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.

    Frei-Kleiner S, Schaffner W, Rahlfs VW et al. · Maturitas 2005 · Black cohosh

    122 women took a different (ethanol-based) black cohosh extract or placebo for 12 weeks. Overall it did not beat placebo; only women with more severe symptoms seemed to benefit, which is a weaker, after-the-fact finding.

    Who
    122 women with ≥3 hot flashes/day
    Dose
    dried ethanolic black cohosh extract (non-Remifemin)
    Duration
    12 weeks
    Result
    No superiority over placebo overall; benefit only in subgroup with moderate–severe symptoms (Kupperman ≥20: -47% vs -21%).
    Funding
    Not stated in abstract. Funding not stated

    PubMed · Full text (DOI)

  • Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract.

    Naser B, Schnitker J, Minkin MJ et al. · Menopause 2011 · Black cohosh

    This analysis of 5 trials found no change in liver blood tests in women taking the Remifemin extract for up to 6 months. It was written by the manufacturer and covers only short-term use.

    Who
    5 RCTs, 1,117 women
    Dose
    iCR 40–128 mg/day
    Duration
    3–6 months
    Result
    No effect on liver enzymes (AST/ALT) vs reference groups.
    Funding
    Written by Schaper & Brümmer (Remifemin maker) staff. Industry-linked

    PubMed · Full text (DOI)

  • United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.

    Mahady GB, Low Dog T, Barrett ML et al. · Menopause 2008 · Black cohosh

    The US Pharmacopeia reviewed 30 reports of liver injury in people using black cohosh. It could not prove black cohosh caused them but recommended a label warning to stop and see a doctor if liver symptoms appear.

    Who
    30 case reports of liver damage
    Dose
    various products
    Duration
    n/a
    Result
    All 30 liver cases rated 'possible' (none probable/certain); USP recommended a cautionary liver label.
    Funding
    US Pharmacopeia expert committee (independent standard-setter). Independent / academic

    PubMed · Full text (DOI)

  • Black cohosh and breast cancer: a systematic review.

    Fritz H, Seely D, McGowan J et al. · Integr Cancer Ther 2014 · Black cohosh

    A systematic review of black cohosh and breast cancer found no sign it increases breast-cancer risk, but also no proof it reduces hot flashes in women who have had breast cancer.

    Who
    26 studies (14 RCTs)
    Dose
    various
    Duration
    various
    Result
    No evidence black cohosh raises breast-cancer risk; no proven hot-flash benefit in breast-cancer patients vs placebo.
    Funding
    Academic (Canadian naturopathic/academic group). Independent / academic

    PubMed · Full text (DOI)

  • Actaea racemosa L. Is More Effective in Combination with Rhodiola rosea L. for Relief of Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study.

    Pkhaladze L, Davidova N, Khomasuridze A et al. · Pharmaceuticals (Basel) 2020 · Black cohosh, Rhodiola

    220 women in Georgia took black cohosh alone, black cohosh plus Rhodiola, or placebo for 12 weeks; the combination worked best. An author is paid by the company that sells the combination.

    Who
    220 women
    Dose
    black cohosh 6.5 mg; black cohosh 500 mg; Rhodiola+black cohosh (Menopause Relief EP); placebo
    Duration
    12 weeks
    Result
    Rhodiola+black cohosh beat black cohosh alone and placebo on all symptom scales.
    Funding
    Author has contract with Europharma USA (seller) and heads Phytomed AB. Industry-linked

    PubMed · Full text (DOI)

  • Complementary therapies for management of menopausal symptoms: a systematic review to inform the update of the International Menopause Society recommendations on women's midlife health.

    Maunder A, Mardon AK, Rao V et al. · Climacteric 2026 · Black cohosh, Vitamin D & calcium

    A 2026 International Menopause Society evidence review rated black cohosh's benefit for hot flashes as moderate-certainty and most other supplements as low-certainty.

    Who
    158 studies
    Dose
    various
    Duration
    n/a
    Result
    Moderate-certainty evidence supports black cohosh for vasomotor/menopausal symptoms and vitamin D for fracture risk; most complementary therapies low/very-low certainty.
    Funding
    International Menopause Society review. Independent / academic

    PubMed · Full text (DOI)

  • Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone.

    Bai W, Henneicke-von Zepelin HH, Wang S et al. · Maturitas 2007 · Black cohosh

    244 Chinese women took Remifemin-type black cohosh or the hormone-like drug tibolone for 12 weeks. Symptom scores fell similarly in both groups, but there was no placebo group, so the size of the true effect is unclear.

    Who
    244 Chinese women
    Dose
    iCR (Remifemin) equivalent to 40 mg/day vs tibolone 2.5 mg/day (no placebo)
    Duration
    12 weeks
    Result
    Kupperman Index fell similarly with iCR and tibolone; iCR better tolerated.
    Funding
    Not stated in abstract. Funding not stated

    PubMed · Full text (DOI)

The Menopause Society's 2023 statement is in the study library.

Price

Regular one-time price$41.99 (60 units, 30 days at label dose)
Cost per day$1.40
Subscription$34.99/bottle
Price notesAmazon B0D5GFJRRL $36.97 (list $42.99)
In stock when checkedYes
CheckedNov 19, 2026

Ratings

Amazon: ★ 4.2 from 2,387 ratings on Amazon (checked Nov 19, 2026)

Brand site: no average shown, 2,421 reviews on opositiv.com (checked Nov 19, 2026). Brand-site reviews are moderated by the brand.

Star ratings reflect buyer satisfaction, not clinical effect.

Certifications and claims

Verified in a public registry

  • No registry listing found.

Claims made by the brand

  • “vegan” Brand claim
  • “hormone-free” Brand claim

Registry check: NSF/ANSI 173 ('O Positiv'): not found

Who's behind it

BrandO Positiv
Owner / companyO Positiv, Inc. (US).
FoundersBrianna Bitton.
Where it's madenot stated.
Medical advisors named
  • Roxanne Pero, MD, FACOG
  • Jessica Shepherd, MD, MBA, FACOG
  • Saru Bala, ND
Sourceopositiv.com

Flags & safety

Legal, regulatory and quality flags

  • Black cohosh liver caution.
  • Systematic review (Natural Product Reports 2024): 42.2% of 322 black cohosh samples across 78 publications adulterated/mislabeled, mainly with Asian Actaea species. pubs.rsc.org
  • DNA barcoding (J AOAC 2012): 9 of 36 (25%) US black cohosh supplements matched Asian Actaea. pubmed.ncbi.nlm.nih.gov

Ingredient safety notes

  • Ashwagandha: Rare liver-injury case reports exist in the literature (not reviewed here); avoid in pregnancy and with thyroid medication — standard cautions (not verified here). Trials reported raised estradiol, lower FSH/LH. Unverified
  • Vitex (chasteberry): Few AEs; avoid with dopaminergic drugs/hormonal contraception (general caution).
  • Black cohosh: Rare liver injury reports (USP: 30 cases 'possible' causality; ODS: ≥83 cases worldwide, causality unproven). USP-recommended label: discontinue if liver disorder or symptoms of liver trouble. No evidence of increased breast-cancer risk (Fritz 2014), but safety after breast cancer not established (NCCIH). Possible interaction with statins (NCCIH).
  • Vitamin D & calcium: Kidney stones increased (WHI HR 1.17). WHI long-term follow-up: CVD mortality HR 1.06, cancer mortality HR 0.93.

Not verified

  • Gummy doses (assumed to match the capsule label). Unverified

Sources

Talk to a clinician first

The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).

If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.